85803-62-9

Basic information

• Product Name: 2-(4-METHYLPIPERAZINO)BENZALDEHYDE
• Synonyms: BUTTPARK 33\06-51;2-(4-METHYLPIPERAZIN-1-YL)BENZALDEHYDE;2-(4-METHYLPIPERAZINO)BENZALDEHYDE;2-(4-Methylpiperazino)benzadehyde
• CAS NO: 85803-62-9
• Molecular Formula: C₁₂H₁₆N₂O
• Molecular Weight: 204.27
• Product Categories: Amino Acid Derivatives
• Mol File: 85803-62-9.mol
• Article Data: 11

Chemical Properties

• Melting Point: 44 °C
• Boiling Point: 110
• Flash Point: 142.3 °C
• Appearance: /
• Density: 1.107 g/cm³
• Vapor Pressure: 0.000152mmHg at 25°C
• Refractive Index: 1.581
• Storage Temp.: 2-8°C
• PKA: 7.69±0.42(Predicted)
• CAS DataBase Reference: 2-(4-METHYLPIPERAZINO)BENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-METHYLPIPERAZINO)BENZALDEHYDE(85803-62-9)
• EPA Substance Registry System: 2-(4-METHYLPIPERAZINO)BENZALDEHYDE(85803-62-9)

Safety Data

• Hazard Codes: C,Xi
• Statements: 36/37/38-36
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 85803-62-9(Hazardous Substances Data)

Usage

General Description

2-(4-Methylpiperazino)benzaldehyde is a chemical compound belonging to the category of organic substances. As its name denotes, the molecular structure comprises a benzaldehyde group, and a 4-methylpiperazine ring. This chemical structure is applicable in the field of organic synthesis where it may serve as an intermediate in the production of other complex compounds. The exact physical and chemical properties such as boiling point, melting point, toxicity, solubility in various solvents, etc. will depend on the specific structure of the compound. It's important to handle all chemical substances with care, observing all necessary safety measures due to potential risks associated with exposure or mishandling.

InChI:InChI=1/C12H16N2O/c1-13-6-8-14(9-7-13)12-5-3-2-4-11(12)10-15/h2-5,10H,6-9H2,1H3

Upstream product

• 109-01-3 1-methyl-piperazine 
• 446-52-6 2-Fluorobenzaldehyde 

Downstream Products

• 112253-36-8 2-[2-(4-Methyl-piperazin-1-yl)-benzylidene]-malononitrile 
• 247157-96-6 1-methyl-4-[2-(2-nitrovinyl)phenyl]piperazine 
• 655256-68-1 (2-(4-methylpiperazin-1-yl)phenyl)methanamine 
• 1095224-50-2 N-methyl-2-(4-methylpiperazin-1-yl)benzylamine 
• 886593-59-5 [2-(4-methylpiperazin-1-yl)phenyl]acetaldehyde 
• 1344706-49-5 1-(1-methyl-1H-indol-3-yl)-3-[2-(4-methyl-piperazin-1-yl)-phenyl]-prop-2-en-1-one 

Relevant articles and documents

Ruthenium catalyzed β-C(sp3)-H functionalization on the 'privileged' piperazine nucleus

β-C(sp3)-H functionalization on the 'privileged' piperazine nucleus has been disclosed using ruthenium catalysis. The ruthenium catalyzed synthesis of a variety of piperazine fused indoles from ortho-piperazinyl (hetero)aryl aldehydes is presented. This transformation takes place via the dehydrogenation of piperazine followed by an intramolecular nucleophilic addition of the transient enamine moiety onto the carbonyl group and aromatization cascade.

PIPERAZINYLPHENALKYL LACTAM/AMINE LIGANDS FOR THE 5HT1B RECEPTOR

The present invention relates to novel derivatives, that are compounds of Formula (I), wherein R1, R2, R3, R14, X, Y, n and m are defined herein, their pharmaceutically acceptable salts, pharmaceutical compositions and methods using said compounds in treating or preventing depression, anxiety, obsessive compulsive disorder (OCD) and other disorders for which selective antagonists, inverse agonists and partial agonists of serotonin 1 (5-HT1) receptors, specifically, antagonists of 5-HT1B are useful.

NOVEL BENZYL(IDENE)-LACTAM DERIVATIVES

The present invention relates to novel benzyl(idene)-lactam derivatives, compounds of the formula (I) wherein R1 is a group of the formula G1 or G2 depicted below, wherein R1, R3, R6, R13, X, a, n and m are as defined herein, their pharmaceutically acceptable salts, and pharmaceutical compositions which include selective antagonists, inverse agonists and partial agonists of serotonin 1 (5-HT1) receptors, specifically, of one or both of the 5-HT1A and 5-HT1B receptors. The compounds of the invention are useful in treating or preventing depression, anxiety, obsessive compulsive disorder (OCD) and other disorders for which a 5-HT1 agonist or antagonist is indicated and have reduced potential for cardiac side effects, in particular QTc prolongation.